Inherited thrombophilia and pregnancy loss

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 634-640

  Brenner, Benjamin ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ANTIPHOSPHOLIPID SYNDROME; CONFERENCE PAPER; FEMALE; FETUS DEATH; GENE MUTATION; HUMAN; INTRAUTERINE GROWTH RETARDATION; PLACENTA CIRCULATION; PREECLAMPSIA; PRIORITY JOURNAL; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; THROMBOPHILIA;

EID: 0032741914     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615890     Document Type: Conference Paper

References (66)

1. Salafia CM, Minior VK, Pezzullo JC, Popek EJ, Rosenkrantz TS, Vintzileos AM. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: Associated placental pathologic features. Am J Obstet Gynecol 1995;173:1049-1057.
2. Brenner B, Blumenfeld Z. Thrombophilia and fetal loss. Blood Rev. 1997;11(2):72-79.
3. Cook CL, Pridham DD. Recurrent pregnancy loss. Curr Opin Obstet Gynecol. 1995;7:357-366.
4. Clifford K, Rai R, Watson H, Regan L. An informative protocol for the investigation of recurrent miscarriage: Preliminary experience of 500 consecutive cases. Hum Reprod. 1994;9:1328-1332.
5. Hatasaka HH. Recurrent miscarriage: Epidemiologic factors, definitions, and incidence. Clin Obstet Gynecol. 1994;37:625-634.
6. Raziel A, Arieli S, Bukovsky I, Caspi E, Golan A. Investigation of the uterine cavity in recurrent aborters. Fertil Steril. 1994;62:1080-1082.
7. Triplett DA, Harris EN. Antiphospholipid antibodies and reproduction. Am J Reprod Immunol. 1989;21:123-131.
8. Beressi AH, Tefferi A, Silverstein MN, Petitt RM, Hoagland WC. Outcome analysis of 34 pregnancies in women with essential thrombocythemia. Arch Intern Med. 1995;155:1217-1222.
9. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin IQ deficiency: Experience of treatment with heparin and antithrombin. Gynecol Obstet Invest. 1982;14:127-141.
10. Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in ATIII, protein C or protein S. Thromb Haemost. 1990;63:319-320.
11. Sanson BJ, Friederich PW, Simioni P, Zanardi S, Hilsman MV, Girolami A, ten Cate JW, Prins MH. The risk of abortion and still-birth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost. 1996;75:387-388.
12. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost. 1995;73:151-161.
13. Gris JC, Schved JF, Neveu S, Mares P, Aguilar-Martinez P, Dupaigne D. Impaired fibrinolytic capacity and early recurrent spontaneous abortions. BMJ. 1990;300:1500.
14. Gris JC, Neveu S, Mares P, Biron C, Hedon B, Schved JF. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortions of unknown etiology. J Lab Clin Med. 1993;122:606-615.
15. Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1995;173:210-213.
16. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
17. Zivelin A, Griffin JH, Xu X, Pabinger I, Samama M, Conard J, Brenner B, Eldor A, Seligsohn U. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood. 1997;89:397-402.
18. Zivelin A, Rosenberg N, Faier S, Kornbrot N, Peretz H, Mannhalter C, Horellou MH, Seligsohn U. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood. 1998;92:1119-1124.
19. Kluijtmans LAJ, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oost BA, den Heijer M, Trijbels FJ, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996;58:35-41.
20. Franco RF, Araujo AG, Guerreiro JF, Elion J, Zago MA. Analysis of the 677C®T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups. Thromb Haemost. 1998;79:119-121.
21. Clark P, Brennand J, Conkie JA, McCall D, Greer IA, Walker ID. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost. 1998;79:1166-1170.
22. Rai R, Regan L, Hadley E, Dave M, Cohen H. Second trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol. 1996;92:489-490.
23. Younis JS, Brenner B, Ohel G, Lanir N, Rothbart M, Ben-Ami M. Factor V Leiden Mutation is associated with first as well as second trimester recurrent fetal loss. Fertil Steril. 1998;70(Suppl 3):S-55.
24. Brenner B, Mandel H, Lanir N, Younis J, Rothbart H, Ohel G, Blumenfeld Z. Activated protein C resistance can be associated with recurrent fetal loss. Brit J Haematol. 1997;97:51-54.
25. Rotmensch S, Liberati M, Mittlemann M, Ben-Rafael Z. Activated protein C resistance and adverse pregnancy outcome. Am J Obstet Gynecol. 1997;177:170-173.
26. Dizon-Townson DS, Kinney S, Branch DW, Ward K. The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol. 1997;34:217-223.
27. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, Fontcuberta J, Makris M, Mariani G, Noteboom W, Pabinger I, Legnani C, Scharrer I, Schulman S, van der Meer FJ. Increased fetal loss in women with heritable thrombophilia. Lancet. 1996;348:913-916.
28. Ridker PM, Miletich JP, Buring JE, Ariyo AA, Price DT, Manson JE, Hill JA. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med. 1998;128:1000-1003.
29. Grandone E, Margaglione M, Colaizzo D, d'Addedda M, Cappucci G, Vecchione G, Scianname N, Pavone G, Di Minno G. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost. 1997;77:822-824.
30. Brenner B, Sarig G, Weiner Z, Younis J, Blumenfeld Z, Lanir N. Thrombophilic polymorphisms in women with fetal loss. Blood. 1998;92(Suppl 1):558a.
31. Pickering W, Holmes Z, Regan L, Cohen H. Normal prevalence of the G20210A prothrombin gene mutation in women with recurrent miscarriage. Br J Haematol. 1998;102(1):250.
32. Deitcher SR, Park VM, Kutteh WH. Prothrombin 20210 G®A mutation analysis in Caucasian women with early first trimester recurrent pregnancy loss. Blood. 1998;92(Suppl 1):118b.
33. Deitcher SR, Park VM, Kutteh WH. Methylene tetrahydrofolate reductase 677C®T mutation analysis in Caucasian women with early first trimester recurrent pregnancy loss. Blood. 1998;92(Suppl 1):117b.
34. Kornberg A, Raziel A, Rahimini-Levene N, Yona R, Sela BA, Ron-El R. Hypercoagulability and recurrent abortions. Blood. 1998;92(Suppl 1):121b.
35. Nelen WL, Blom HJ, Thomas CM, Steegers EA, Boers CH, Eskes TK. Methylenetetrahydrofolate reductase polymorphism affects the change in homocysteine and folate concentrations resulting from low dose folic acid supplementation in women with unexplained recurrent miscarriages. J Nutr. 1998;128:1336-1341.
36. Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood. 1995;85:3518-3523.
37. Brenner B, Zivelin A, Lanir N, Greengard JS, Griffin JH, Seligsohn U. Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C deficient newborn with massive thrombosis. Blood. 1996;88:877-880.
38. Mandel H, Brenner B, Berant M, Rosenberg N, Lanir N, Jakobs C, Fowler B, Seligsohn U. Coexistence of hereditary homocysteinuria and factor V Leiden - effect on thrombosis. N Engl J Med. 1996;334:763-768.
39. Brenner B, Vulfsons SL, Lanir N, Nahir M. Coexistence of familial antiphospholipid syndrome and factor V Leiden - impact on thrombotic diathesis. Br J Haematol. 1996;94:166-167.
40. Brenner B, Zwang E, Bronshtein M, Seligsohn U. Von Willebrand factor multimer patterns in pregnancy-induced hypertension. Thromb Haemost. 1989;62:715-717.
41. Cadroy Y, Grandjean H, Pichon J, Desprats R, Berrebi A, Boneu B. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or preeclampsia. Br J Obstet Gynecol. 1993;100:416-420.
42. Higgins JR, Walshe JJ, Darling MR, Norris L, Bonnar J. Hemostasis in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnancies. Am J Obstet Gynecol. 1998;179:520-526.
43. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol. 1996;175:902-905.
44. Nagy B, Toth T, Rigo J Jr, Karadi I, Romics L, Papp Z. Detection of factor V Leiden mutation in severe pre-eclamptic Hungarian women. Clin Genet. 1998;53:478-481.
45. Brenner B, Lanir N, Thaler I. HELLP syndrome associated with factor V R506Q mutation. Br J Haematol. 1996;92:999-1001.
46. Krauss T, Augustin HG, Osmers R, Meden H, Unterhalt M, Kuhn W. Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol. 1998;92:457-460.
47. Dekker GA, de Vries JI, Doelitzsch PM, Huijgens PC, von Blomberg BM, Jakobs C, van Geijn HP. Underlying disorders associated with severe early onset preeclampsia. Am J Obstet Gynecol. 1995;173:1042-1048.
48. Grandone E, Margaglione M, Colaizzo D, Cappucci G, Paladini D, Martinelli P, Montanaro S, Pavone G, Di Minno G. Factor V Leiden, C®T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost. 1997;77:1052-1054.
49. de Vries JIP, Dekker GA, Huijgens PC, Jakobs C, Blomberg BM, van Geijn HP. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol. 1997;104:1248-1254.
50. Goddijn-Wessel TA, Wouters MG, van der Molen EF, Spuijbrock MD, Steegers-Theunissen RP, Blom HJ, Boers GH, Eskes TK. Hyper-homocysteinemia: a risk factor for placental abruption or infarction. Eur J Obstet Gynecol Reprod Biol. 1996;66:23-29.
51. nd International Symposium on Homocysteine, Netherlands J Med. 1998;52:S54.
52. Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E. Resistance to activated protein C and the Leiden mutation: high prevalence in patients with abruptio placentae. J Obstet Gynecol. 1998;179:1565-1567.
53. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB. Increased frequency of genetic thrombophilias in women with complications of pregnancy. N Engl J Med. 1999;340:9-13.
54. Grandone E, Margaglione M, Colaizzo D, D'Andrea G, Cappucci G, Brancaccio V, Di Minno G. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol. 1998;179:1324-1328.
55. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174:1584-1589.
56. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with antiphospholipid antibodies. BMJ. 1997;314:253-257.
57. Sanson BJ, Lensing AWA, Prins MH, Ginsberg JS, Barkagen ZS, Lavenne-Pardonge E, Brenner B, Dulitzky M, Nielsen JD, Boda Z, Turi S, MacGillavry M, Hamulyak K, Theunissen IM, Hunt BJ, Buller HR. Safety of low molecular weight heparin in pregnancy. A systematic review. Thromb Haemostes 1999;81:668-72.
58. Gris JC, Neveu S, Tailland ML, Courtieu C, Mares P, Schved JF. Use of low-molecular weight heparin (Enoxaparin) or of a phenformin-like substance (Moroxydine chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity. Thromb Haemost. 1995;73:362-367.
59. Benigni A, Gregorini G, Frusca T, Chiabrando C, Ballerini S, Valcamonico A, Orisio S, Piccinelli A, Pinciroli V, Fanelli R. Effect of low dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy induced hypertension. N Engl J Med. 1989;321:357-362.
60. Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, Van Dorsten P, Landon M, Paul R, Miodovnik M, Meis P, Thurnau G. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1998;38:701-705.
61. Riyazi N, Leeda M, de Vries JI, Huijgens PC, van Geijn HP, Dekker GA. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: A preliminary study. Eur J Obstet Reprod Biol. 1998;80:49-54.
62. Eldor A, Kupferminc MJ, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB. High incidence of thrombophilia in women with obstetric complications and the beneficial effects of LMW heparin and aspirin in subsequent pregnancies. Blood. 1998;92(Suppl 1):556a.
63. Roussev RG, Stern JJ, Kaider BD, Thaler CJ. Anti-endothelial cell antibodies: another cause for pregnency loss? Am J Reprod Immunol. 1998;39:89-95.
64. Tedesco F, Pausa M, Nardon E, Narchi G, Bulla R, Livi C, Guaschino S, Meroni PL. Prevalence and biological effects of anti-trophoblast and anti-endothelial cell antibodies in patients with recurrent spontaneous abortions. Am J Reprod Immunol. 1997;38:205-211.
65. Rand JH, Wu X-X, Andree HAM, Lockwood CJ, Guller S, Scher J, Harpel PC. Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism. N Engl J Med. 1997;337:154-160.
66. Mercier E, Quere I, Mares P, Gris JC. Primary recurrent miscarriages: anti-b2 glycoprotein I IgG antibodies induce an acquired activated protein C resistance that can be detected by the modified activated protein C resistance test. Blood. 1998;92:2993-2994.